[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100437499":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":25,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":25,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":25,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Zuyderland Medisch Centrum","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Interrupted DOAC use (group 1)","ACTIVE_COMPARATOR","Patients in group 1 will receive standard care. Therefore, DOAC use will be interrupted at least 24 hours in advance of ICA or PCI. Based on the renal clearance, last DOAC intake may be extended to 48 hours prior to the procedure \\[Table 2\\]. After the procedure, patients will continue using their DOAC as usual.",[13],"Other: Interrupted DOAC use",{"label":15,"type":16,"description":17,"interventionNames":18},"Uninterrupted DOAC use (group 2)","EXPERIMENTAL","In group 2, all patients will continue to use their specific DOAC as usual. This means that no adjustments of DOAC use will be made before and after ICA or PCI. After the procedure patients will continue to use DOAC from the next planned dose.",[19],"Other: Uninterrupted DOAC use",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Uninterrupted DOAC use","Continuing DOAC use in advance of elective ICA or PCI.",[15],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Interrupted DOAC use","Usual care, interruption of DOAC prior to procedure.",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Sanne Janssen, MSC","CONTACT","08854597522","sanne.janssen@zuyderland.nl",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Zuyderland MC","RECRUITING","Heerlen","Limburg","6419PC","Netherlands","NL",{"type":46,"coordinates":47},"Point",[48,49],5.98154,50.88365,{"lat":49,"lon":48},[52],{"name":53,"role":33,"phone":25,"phoneExt":25,"email":35},"Sanne Janssen, MSc",{"type":55,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100437499","comparison-between-direct-oral-anticoagulation-doac-interruption-and-doac-continuation-in-patients-undergoing-elective-invasive-coronary-angiography-or-percutaneous-coronary-intervention-100437499",false,"NCT04977076","Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention","SLIM-2","Inclusion Criteria:\n\n* Patients aged \\>18 years using DOAC and undergoing elective ICA or PCI.\n* Provided signed informed consent\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\nAny of the following:\n\n* Patients initially presenting with Acute Coronary Syndrome (STEMI, NSTEMI, UA)\n* Patients \\\u003C18 years old\n* Calculated creatinine clearance \\\u003C30 mL\u002Fmin\n* Patients simultaneously participating in another clinical trial\n* History or condition associated with increased bleeding risk, as listed below:\n\n  * Major surgical procedure within 30 days before the procedure\n  * Known inaccessible radial artery during previous procedure\n  * History of GI bleeding in the previous 6 months\n  * History of intracranial, intraocular, spinal, or atraumatic intra-articular bleeding\n  * Chronic bleeding disorder\n  * Known intracranial neoplasm, arteriovenous malformation, or aneurysm\n  * Known anemia with last measured haemoglobin value \\\u003C6 mmol\u002FL \\[9.67 g\u002FdL\\]\n  * Current pregnancy or breast-feeding\n  * Known significant liver disease (e.g., acute clinical hepatitis, chronic active hepatitis, cirrhosis), or Alanine aminotransferase (ALT) \\>3 x the upper limit of normal.\n* Participation in another clinical trial","ALL","18 Years",{"count":66,"type":67},1270,"ESTIMATED","INTERVENTIONAL",[70],"NA","A prospective, multicenter, 1:1 randomized, investigator initiated study. Goal of this study is to examine the safety of uninterrupted periprocedural DOAC use.",[73,74,75],"Atrial Fibrillation","Coronary Artery Disease","Anticoagulants","2026-05-26",{"date":78,"type":79},"2026-05-29","ACTUAL",{"date":81,"type":79},"2022-09-01",{"date":83,"type":67},"2027-12-31",{"name":5,"class":6},1]